Ontology highlight
ABSTRACT:
SUBMITTER: Hirsh V
PROVIDER: S-EPMC4257116 | biostudies-other | 2014 Dec
REPOSITORIES: biostudies-other
Hirsh V V Blais N N Burkes R R Verma S S Croitoru K K
Current oncology (Toronto, Ont.) 20141201 6
Treatment for non-small-cell lung cancer (nsclc) is moving away from traditional chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) erlotinib and gefitinib were developed to target the epidermal growth factor receptor (egfr). Afatinib, an irreversible ErbB family blocker, was developed to block egfr (ErbB1), human epidermal growth factor receptor 2 (ErbB2), and ErbB4 signalling, and transphosphorylation of ErbB3. All of the foregoing agents are efficaciou ...[more]